Edition:
United Kingdom

Kala Pharmaceuticals Inc (KALA.OQ)

KALA.OQ on NASDAQ Stock Exchange Global Select Market

9.23USD
19 Oct 2018
Change (% chg)

$-0.31 (-3.25%)
Prev Close
$9.54
Open
$9.54
Day's High
$9.77
Day's Low
$9.19
Volume
67,965
Avg. Vol
84,642
52-wk High
$22.02
52-wk Low
$7.60

Latest Key Developments (Source: Significant Developments)

Kala Pharmaceuticals Announces Financing From Athyrium Capital Management Totaling $110 Million
Tuesday, 2 Oct 2018 

Oct 2 (Reuters) - Kala Pharmaceuticals Inc ::KALA PHARMACEUTICALS ANNOUNCES FINANCING FROM ATHYRIUM CAPITAL MANAGEMENT TOTALING $110 MILLION.KALA PHARMACEUTICALS INC - EXPECT THE FINANCING TO SUPPORT KALA'S EFFORTS TO ACHIEVE SIGNIFICANT MILESTONES.KALA PHARMACEUTICALS INC - EXPECTS NDA FILING FOR KPI-121 0.25% FOR DRY EYE DISEASE BY END OF 2018, LAUNCH OF INVELTYS IN EARLY 2019.KALA PHARMACEUTICALS INC - EXPECTS TOPLINE RESULTS FOR STRIDE-3 TRIAL OF KPI-121 0.25% EXPECTED IN Q4 2019.KALA PHARMACEUTICALS INC - CLOSING OF KALA'S $110 MILLION CREDIT FACILITY WITH FUNDS MANAGED BY ATHYRIUM CAPITAL MANAGEMENT.  Full Article

Kala Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Tuesday, 2 Oct 2018 

Oct 2 (Reuters) - Kala Pharmaceuticals Inc ::KALA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.KALA PHARMACEUTICALS INC - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF 7.5 MILLION SHARES OF ITS COMMON STOCK.  Full Article

Kala Pharmaceuticals Inveltys Wins FDA Approval
Thursday, 23 Aug 2018 

Aug 23 (Reuters) - :KALA PHARMACEUTICALS INVELTYS WINS FDA APPROVAL.  Full Article

Kala Pharmaceuticals Announces FDA Approval Of Inveltys
Thursday, 23 Aug 2018 

Aug 23 (Reuters) - Kala Pharmaceuticals Inc ::KALA PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF INVELTYS™ FOR THE TREATMENT OF POST-OPERATIVE INFLAMMATION AND PAIN FOLLOWING OCULAR SURGERY.SAYS EXPECTS TO REPORT TOP-LINE RESULTS FOR STRIDE 3 IN Q4 OF 2019.SAYS EXPECT TO LAUNCH INVELTYS IN BEGINNING OF 2019.SAYS PLANS TO SUBMIT A NEW DRUG APPLICATION FOR KPI-121 0.25% DURING H2 OF 2018.  Full Article

Kala Pharmaceuticals Inc Files For Mixed Shelf Of Upto $250 Million
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Kala Pharmaceuticals Inc ::KALA PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $250 MILLION - SEC FILING.KALA PHARMACEUTICALS INC SAYS IN ADDITION, ENTERED INTO SALES AGREEMENT WITH JEFFERIES LLC FOR SALE OF SHARES OF CO'S COMMON STOCK OF UP TO $50.0 MILLION.  Full Article

Kala Pharmaceuticals Q2 Loss Per Share $0.60
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Kala Pharmaceuticals Inc ::KALA PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.60.Q2 EARNINGS PER SHARE VIEW $-0.50 -- THOMSON REUTERS I/B/E/S.  Full Article

Kala Pharmaceuticals Reports Q1 Loss Per Share Of $0.46
Thursday, 10 May 2018 

May 10 (Reuters) - Kala Pharmaceuticals Inc ::KALA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.46.Q1 EARNINGS PER SHARE VIEW $-0.45 -- THOMSON REUTERS I/B/E/S.AS OF MARCH 31, 2018, HAD CASH OF $100.5 MILLION COMPARED TO $114.6 MILLION AS OF DECEMBER 31, 2017.ANTICIPATES THAT ITS EXISTING CASH ON HAND WILL ENABLE IT TO FUND OPERATIONS THROUGH AT LEAST NEXT TWELVE MONTHS.  Full Article

Kala Pharmaceuticals Posts Q4 Loss Per Share $0.46
Monday, 26 Mar 2018 

March 26 (Reuters) - Kala Pharmaceuticals Inc ::KALA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.46.Q4 EARNINGS PER SHARE VIEW $-0.37 -- THOMSON REUTERS I/B/E/S.ENDED 2017 WITH $114.6 MILLION IN CASH.PDUFA TARGET ACTION DATE FOR INVELTYS IS AUGUST 24, 2018.  Full Article

Orbimed Advisors Reports About 11 Pct Passive Stake In Kala Pharmaceuticals
Friday, 12 Jan 2018 

Jan 12 (Reuters) - Kala Pharmaceuticals Inc ::ORBIMED ADVISORS LLC REPORTS ABOUT 11 PERCENT PASSIVE STAKE IN KALA PHARMACEUTICALS INC AS OF JAN 10.  Full Article

Kala Pharmaceuticals Announces Topline Results For Two Phase 3 Trials Of Kpi-121
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Kala Pharmaceuticals Inc ::KALA PHARMACEUTICALS ANNOUNCES TOPLINE RESULTS FOR TWO PHASE 3 TRIALS (STRIDE 1 AND STRIDE 2) OF KPI-121 0.25% IN DRY EYE DISEASE.KALA PHARMACEUTICALS INC - KPI-121 0.25% WAS WELL-TOLERATED WITH ELEVATIONS IN IOP SIMILAR TO PLACEBO.KALA PHARMACEUTICALS INC - IN STRIDE 1 TRIAL, STATISTICAL SIGNIFICANCE WAS ACHIEVED FOR PRIMARY SIGN ENDPOINT.KALA PHARMACEUTICALS- OCULAR DISCOMFORT SEVERITY AT DAY 15 IN ITT POPULATION SHOWED IMPROVEMENT BUT DID NOT REACH STATISTICAL SIGNIFICANCE IN STRIDE 2.KALA PHARMACEUTICALS INC - IN STRIDE 2 TRIAL, STATISTICAL SIGNIFICANCE WAS ACHIEVED FOR PRIMARY SIGN ENDPOINT.KALA PHARMACEUTICALS INC - WILL CONTINUE TO ANALYZE RESULTS OF BOTH PHASE 3 TRIALS.  Full Article

U.S. FDA approves Kala Pharma's eye pain drug

Aug 23 The U.S. Food and Drug Administration on Thursday approved Kala Pharmaceuticals Inc's treatment for reducing inflammation and pain following an eye surgery.